From natural ecology [1] [2] [3] [4] to clinical therapy [5] [6] [7] [8] , cells are often exposed to mixtures of multiple drugs. Two competing null models are used to predict the combined effect of drugs: response additivity (Bliss) and dosage additivity (Loewe) [9] [10] [11] . Here, noting that these models diverge with 
Main Text:
In both nature and the clinic, cells are often exposed to combinations of multiple stresses and drugs. In natural ecosystems, such as the soil, dozens of microbial species capable of producing different antimicrobial compounds coexist in very close proximity, thus exposing each-others to a mixture of multiple stressors [1] [2] [3] [4] . In clinical settings, drug combinations, aimed at reducing side effects and counteracting resistance [13] [14] [15] [16] [17] , are becoming increasingly important in treatment for infectious diseases and cancer [5] [6] [7] [8] 18, 19 . It is therefore of wide importance to understand how cell growth is affected by combinations of multitude of stressors and what are thereby the general rules of high-dimensionality drug arithmetics.
When combined together, drugs can interact to synergize or antagonize each other effects relative to a null additive model. Synergy occurs when the combined effect of drugs is larger than expected based on their individual effects. Conversely, drugs can also antagonize each other, leading to a combined effect that is smaller than expected. These interactions are important in clinical settings as a way of increasing treatment potency and selectivity [20] [21] [22] or slowing selection for resistance 14, 17, 23 . Importantly, the definition of both synergy and antagonism relies on comparing the effect of drug combinations with a null model of "additive expectation" 6, [24] [25] [26] [27] .
There are two primary models for the null effect of drug combinations 6, 28 : the Bliss model 10, 29 , which assumes response additivity and the Loewe model 9,11 , which assumes dose additivity.
According to Bliss, the combined effect of two drugs is simply the sum of their individual E 1+2 effects 30 , , where is the effect of drug on the normalized growth Fig. 1 ; when effects are measured based on total yield rather than growth rate, Bliss /g g 0 additivity becomes multiplicativity; Supplementary Note 1). In contrast, according to Loewe additivity, the effect of drugs in combination is determined not by the sum of their normalized effects, but rather by the sum of their normalized dosages, such that their combined effect is the same across all combinations that have the same total normalized dosage. Namely, according to Loewe, lines of equal combination effect in drug-dosage space (isoboloes), are linear 26 To contrast the Bliss and Loewe models, we calculated how their predictions scale with increased number of drugs. As a natural measure of the combined potency of multiple drugs, we considered the total drug dosage needed to achieve a given level of inhibition. 
coefficient, and equating the Bliss prediction of the combined effect to 50%,
yields the Bliss predicted scaling of combination potency with the number of drugs:
. Thus, while Loewe predicts that the total dosage required for
inhibition is constant, Bliss predicts that it increases with the number of drugs. The two models can therefore best be contrasted by measuring the combined action of increased number of drugs.
We considered 10 mechanistically different antibiotics and measured their effects on the growth rate of Escherichia coli populations, individually as well as in combinations of increased number of drugs. We chose antibiotics acting on a range of cellular functions, including cell wall synthesis, DNA replication, transcription and translation (Table 1) and 2c, response surface and IC50 isoboles) 41, 42 of all points satisfying , Methods). As expected, the measured
IC50 isobole lie above these predictions for the TET-CIP pair (indicating antagonism) and below for the TET-ERY pair (indicating synergy). While these two-dimensional gradients allow clear definition of synergy and antagonism, they require many growth measurements and become combinatorially prohibitive in a high-dimensional multi-drug space.
To effectively sample the concentrations space of multiple drugs, we performed growth measurements along a "co-potent" line 38 , a curve in concentration space where the individual drugs have equal potencies in isolation ( , Figs 2b-e) . This co-potent ) ) .. ) Comparing these combination potencies with predictions of the Bliss and Loewe null models, we find that both positive ( , antagonism) and negative ( , synergism) deviations are ε > 0 ε < 0 prevalent with respect to either model (Figs 2f and 2g ). This prevalence of both antagonism and synergy among drug pairs overwhelms any small deviations between the two models ( Fig. 2g; 0.40; 0.41; =0.06, t-test: P=0.49). Further, clustering (ε ) σ Bliss = (ε ) σ Loewe = −< < ε Bliss > ε Loewe > drugs based on these pairwise interactions, defined with respect to either Bliss or Loewe, leads to similar grouping by mechanism of action (Extended Data Fig. 7 ; possible small advantage to Bliss in resolving fine functionality differences) 43 . The similarity of pairwise null predictions, the prevalence and magnitude of pairwise interactions with respect to both models, and their similar correlation with cellular function, prohibit distinction of the Loewe and Bliss null models based on drug pairs.
However, for increasing numbers of drugs, we find that their combined effect is well predicted by Bliss, while the Loewe prediction systematically diverges. Given that predictions of the two models should diverge with increased number of drugs, we measured the combined effect of multiple combinations with a varying number of antibiotics. We chose 35 combinations of three to ten antibiotics, including 8 randomly chosen sets from each combination size of =3, 5 and 7 N drugs, all 10 sets of 9 drugs, and the whole 10-drug set (Figs 3a and 3b, Extended Data Fig. 8 ).
Following the procedure used for the drug pairs, we measured the combined effect of each multi-drug set as a function of total dosage along co-potent lines and identified their combination potencies . Contrasting these measured potencies with the predicted potencies of Bliss and D
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Loewe based on the single-drug measurements, we find that the Bliss model maintain good accuracy regardless of the number of drugs, while the accuracy of Loewe model declines as the number of drugs increases (Fig. 3c) . The multiplicative form of the Bliss model (more suitable for yield measurements, Supplementary Note 1) is less predictive than the additive form, yet still much better compared to Loewe (Extended Data Fig. 9 ). We conclude that the Loewe model, predicting that the total dosage required for inhibition is fixed regardless of the number of drugs, can be rejected as a general predictor for the potency of multi-drug combinations.
Next, we tested how the potency of drug combinations, namely the total dosage required for inhibition, varies with the number of drugs. To account for any slight experimental deviations from the ideal co-potent line, we use a natural entropy-like definition of an effective number of drugs which is based on the uniformity of the individual drug effects ( equals if all N ef f N ef f N drugs have the same effect; is slightly smaller than N when these effects are uneven; and converges to 1 at the extreme case when a single drug dominates and all the other have no effect; see definition of in Fig. 4 caption) . Contrary to the Loewe prediction, we find that the N ef f total dosage required for inhibition increases with the effective number of drugs (Fig. 4a) .
Moreover, this inhibitory total dosage seems to obey a simple scaling law: it increases as the consistent with the drug combination measurements (Fig. 4d ). Yet, unlike Bliss these predictions do not require fine measurements of the minute individual drug effects , but rather depend Extended Data Table 3 ), which predict the potency of drug combinations similarly well and explain the square-root scaling law of potency with number of drugs.
Our measurements reject the Loewe model of dosage-additivity for predicting combination of multiple diverse drugs, favoring the Bliss effect-additivity and motivating a simple model of dosage-orthogonality. In contrast to Loewe additivity, which predicts that the total dosage required for inhibition is fixed, we find that the total inhibitory dosage increases with the number of drugs, following a square root scaling law. This general reduction in potency with increased number of drugs implies that bacterial inhibition by multi-drug combinations may be require higher total drug dosages than classically anticipated. The square root scaling supports a model for drug additivity where dosages of independent drugs add up orthogonally rather than linearly.
This dosage-orthogonality model provides an approximation to Bliss, yet it uses dosage arithmetics which allows a more robust implementation and simple intuition. It will be interesting to explore the generality of these results and the limit on the number of orthogonal pharmacological axes as more antibiotics and stresses are added, as well as beyond the minimal inhibitory concentration and in more complex systems such as in cancer therapy.
Throughout such clinical systems and natural ecologies, our findings provide a uniform framework for understanding the null arithmetics of many-drug combinations. , where
